BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

Lee, J.; Ahmed, Tasnia; Maurichi, Andrea; Guardo, Lorenza Di; Stagno, Anna; Warburton, Lydia; Taylor, Amanda; Livingstone, Elisabeth; Rehman, S.; Khattak, Adnan; Kähler, Katharina C.; Vanella, Vito; Atkinson, Victoria; Millward, Michael; Schadendorf, Dirk; Johnson, Douglas B.; Ascierto, Paolo A.; Hauschild, Axel; Lo, Serigne; Long, Georgina V.; Menzies, Alexander M.; Carlino, Matteo S.

doi:10.1016/j.ejca.2022.11.009

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another multicenter, retrospective study, 36 (38%) of 94 patients who discontinued targeted therapy during the progression‐free stage (67 with CR, 21 with PR, and two with stable disease) finally progressed after a median follow‐up of 42.9 months. The initial treatment duration was shorter in patients who exhibited disease progression (median 18.3 months) compared to that in patients who did not (median 34.6 months) 60 . Both studies reported a strong association between treatment duration and reduced risk of progression following treatment cessation.…”

Section: Optimal Duration Of Systemic Therapymentioning

confidence: 92%

“…The initial treatment duration was shorter in patients who exhibited disease progression (median 18.3 months) compared to that in patients who did not (median 34.6 months). 60 Both studies reported a strong association between treatment duration and reduced risk of progression following treatment cessation. Although sustained disease control beyond the cessation of targeted therapy is possible in some cases, novel predictive biomarkers are necessary to identify patients who can safely discontinue targeted therapy.…”

Section: Targeted Therapymentioning

confidence: 99%

“…Several retrospective studies have reported the clinical outcomes of targeted therapies after early discontinuation of BRAF/MEK inhibitors for advanced BRAF V600-mutant melanoma. [58][59][60] In a retrospective study using the multicenter skin cancer registry ADOReg of the Dermatologic Cooperative Oncology Group (DeCOG), 461 patients received first-line BRAF or BRAF/MEK inhibitors, and 37 patients subsequently achieved CR. Of these, all 11 patients who continued therapy until the data cut-off maintained a CR, whereas 22 of the 26 patients (85%) who discontinued therapy eventually relapsed.…”

Section: Targeted Therapymentioning

confidence: 99%

See 2 more Smart Citations

Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?

Namikawa,

Nakano,

Ogata

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Immune checkpoint inhibitors have been shown to prolong survival of patients with several types of cancer, and the finding was first established in melanoma. Previously, systemic therapy for advanced melanoma aimed only at tumor control and palliation of symptoms. However, in recent years, some patients who received systemic therapy have achieved a complete response and survived without continuous treatment for more than several years. This review discusses the long‐term survival rates achieved with currently used systemic therapies and their future perspectives. Long‐term survival is currently most likely to be achieved with the use of the standard‐dose combination of nivolumab plus ipilimumab, however, this regimen is associated with a high frequency of serious or persistent immune‐related adverse events. Several new anti‐PD‐1‐based combination therapies with a better risk–benefit balance are currently under development. Although the acral and mucosal subtypes tend to be less responsive to immune checkpoint inhibitors, anti‐PD‐1‐based combination therapy should continue to be investigated for these subtypes owing to its potential for better long‐term survival. With the development of efficacious immunotherapy and targeted therapy, it is important to determine the optimal duration of systemic therapy to avoid unnecessary health and financial burdens as well as to improve efforts to support long‐term cancer survivors. As the goal of systemic therapy shifts from tumor control to long‐term survival, in future clinical trials, long‐term clinical outcomes should be evaluated to assess the benefits of novel agents.

show abstract

Section: Optimal Duration Of Systemic Therapymentioning

confidence: 92%

Section: Targeted Therapymentioning

confidence: 99%